Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Pregnancy ANtihypertensive Drugs: which Agent is best?

The aim of this study is to evaluate the effect of different antihypertensive drugs in women with pregnancy hypertension on maternal and fetal/neonatal outcomes.

Giant Panda

ABOUT THE STUDY

 The primary objective is to evaluate if treatment with nifedipine (calcium channel blocker), compared to labetalol (mixed alpha/beta blocker) in women with pregnancy hypertension, reduces severe maternal hypertension without increasing fetal or neonate adverse events.

 

WHO CAN PARTICIPATE IN THIS STUDY? 

Inclusion criteria

11+0 – 34+6 weeks

Diagnosis of pregnancy hypertension (Chronic/gestational or Pre-eclampsia)

>18 years old

Clinicians’ decision to initiate antihypertensive drugs

 

Exclusion criteria

Contraindication to either Labetalol or Nifedipine

Already taking both medications.

 

What to expect

  • You will be randomly assigned to receive one of two drugs Nifedipine or Labetalol. Both of these medications for blood pressure are usual clinical practice.
  • Observational: Data input only (for the women who are eligible but excluded due to contraindication to either medication or women already taking both antihypertensive drugs)
  • Post randomisation contact – safety check after 2 weeks
  • Post randomisation contact – after 6 weeks (4 weekly thereafter)

 

For further information, please read our study leaflet.

 

HOW CAN I GET INVOLVED?

Giant Panda Research Team

Nuffield Department of Women’s and Reproductive Health, University of Oxford

The Women’s Centre, John Radcliffe Hospital

Oxford

OX3 9DU

Phone: 01865 221107/07925148248

Email: OSPREA@wrh.ox.ac.uk

 

Ethical Approval

This study has been ethically approved by the London - South East Research Ethics Committee.

REC number: 20/LO/1110

Our team

Key Information

Principal Investigator - Doctor Lucy Mackillop

Chief Investigator - Professor Lucy Chappell

Sponsor – University of Birmingham. The co-ordinating centre for the trial is Birmingham clinical trials unit.

Contact Form

If you would like to find out more about taking part in research with the OSPREA Research Centre please call us on 01865 572258. Alternatively please fill out the contact form.

See Form

Where we work

The OSPREA Research Centre is located on Level 4, Women's Centre, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX9 3DU. The unit is connected to the Ultrasound Department the entrance is through the Ultrasound Department waiting area.

See sites